Abstract
Introduction Nivolumab, a programmed death-1(PD-1) inhibitor antibody, have demonstrated anti-tumor activity for multiple malignancies. Such immune ch......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
